Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 30, 2013
January 26, 2021
2ee1cd52-3926-4b4e-8acb-2ae6e7eea9c8
Related Documents
Expedited Programs for Serious Conditions | Drugs and Biologics
Guidance DocumentMay 30, 2014Center for Drug Evaluation and Research
CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports
Guidance DocumentMarch 5, 2014Center for Drug Evaluation and Research
User Fee Waivers, Reductions, and Refunds for Drug and Biological Products
Guidance DocumentSeptember 27, 2011Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox